Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00447382
Recruitment Status : Completed
First Posted : March 14, 2007
Results First Posted : May 12, 2011
Last Update Posted : October 9, 2014
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and South Africa. The aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (NN729) with insulin detemir made by the previous production method (NN304). Subjects were treated with NN729 or NN304 for a period of 52 weeks at the same total daily dose and frequency of administration as their own pre-trial basal insulin . During the trial doses were individualised based on subject's plasma glucose measurements.

Condition or disease Intervention/treatment Phase
Diabetes Diabetes Mellitus, Type 1 Drug: insulin detemir Drug: insulin aspart Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin
Study Start Date : March 2007
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Active Comparator: NN304
Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
Drug: insulin detemir
NN304 injected s.c. (under the skin). Given as basal insulin.

Drug: insulin aspart
Injected s.c. (under the skin). Given as bolus insulin.

Experimental: NN729
Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
Drug: insulin aspart
Injected s.c. (under the skin). Given as bolus insulin.

Drug: insulin detemir
NN729 injected s.c. (under the skin). Given as basal insulin




Primary Outcome Measures :
  1. Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies [ Time Frame: week 0, week 52 ]
    Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.


Secondary Outcome Measures :
  1. Hypoglycaemic Episodes [ Time Frame: Weeks 0-52 ]
    Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.

  2. Glycaemic Control Parameters (Change in HbA1c) [ Time Frame: week 0, week 52 ]
    HbA1c (Glycosylated haemoglobin).

  3. Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG]) [ Time Frame: week 0, week 52 ]
  4. Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG]) [ Time Frame: week 0, 26 and 52 ]
    1. point is Before Breakfast
    2. point is 120 minutes after Breakfast
    3. point is Before Lunch
    4. point is 120 minutes after Lunch
    5. point is Before Dinner
    6. point is 120 minutes after Dinner
    7. point is at Bedtime
    8. point is At 03:00 A.M.
    9. point is Before Breakfast the Following Day

  5. Change From Baseline in Detemir Specific Antibodies [ Time Frame: Week 0, week 52 ]
    Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.

  6. Change From Baseline in Total Antibodies [ Time Frame: Week 0, week 52 ]
    Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir - human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.

  7. Clinical Laboratory Values (Change in Haematology - Basophilis) [ Time Frame: week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.

    Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.


  8. Clinical Laboratory Values (Change in Haematology - Eosinophils) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.

  9. Clinical Laboratory Values (Change in Haematology - Haemoglobin) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.

  10. Clinical Laboratory Values (Change in Haematology - Lymphocytes) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.

    Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.


  11. Clinical Laboratory Values (Change in Haematology - Monocytes) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.

    Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.


  12. Clinical Laboratory Values (Change in Haematology - Neutrophils) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.

    Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.


  13. Clinical Laboratory Values (Change in Haematology - Thrombocytes) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.

  14. Clinical Laboratory Values (Change in Haematology - Leucocytes) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.

    Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.


  15. Clinical Laboratory Values (Change in Biochemistry - Albumin) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory

  16. Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT]) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.

    (ALAT = alanine aminotransferase)


  17. Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP]) [ Time Frame: Week 0, week 52 ]

    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.

    (ALP = alkaline phosphatase)


  18. Clinical Laboratory Values (Change in Biochemistry - Creatinine) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory

  19. Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH]) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)

  20. Clinical Laboratory Values (Change in Biochemistry - Potassium) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory

  21. Clinical Laboratory Values (Change in Biochemistry - Sodium) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory

  22. Clinical Laboratory Values (Change in Biochemistry - Total Protein) [ Time Frame: Week 0, week 52 ]
    Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory

  23. Adverse Events [ Time Frame: Weeks 0-52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetes for at least 12 months
  • Basal-bolus treatment for at least 3 months
  • Body Mass Index (BMI) less than or equal to 35.0 kg/m^2
  • HbA1c (glycosylated haemoglobin) less than or equal to 12.0%

Exclusion Criteria:

  • Known or suspected allergy to trial products or related products
  • Pregnancy, breast-feeding or the intention to become pregnant or not using adequate contraceptive measures
  • Receipt of any trial drug within 1 month prior to this trial
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Conditions that may interfere with trial participation as judged by Investigator: proliferative retinopathy or maculopathy requiring acute treatment within the last six months, recurrent major hypoglycaemia, impaired hepatic or renal function, cardiac problems, uncontrolled hypertension (treated and untreated)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00447382


Locations
Layout table for location information
Former Serbia and Montenegro
Belgrade, Former Serbia and Montenegro, 11000
Germany
Frankfurt, Germany, 60590
Macedonia, The Former Yugoslav Republic of
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Russian Federation
Moscow, Russian Federation, 119034
South Africa
Cape Town, Western Cape, South Africa, 7925
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S

Additional Information:
Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00447382    
Other Study ID Numbers: EX1729-1778
2006-004733-15 ( EudraCT Number )
First Posted: March 14, 2007    Key Record Dates
Results First Posted: May 12, 2011
Last Update Posted: October 9, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Insulin Aspart
Insulin, Long-Acting
Insulin degludec, insulin aspart drug combination
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs